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Contiguous bilateral head and neck
paragangliomas in a carrier of the SDHB germline
mutation
Nicole Collins, DO,a and Alan Dietzek, MD, FACS, RPVI,b Burlington, Vt; and Danbury, Conn
Paragangliomas are extremely rare neoplasms with multicentric presentation usually linked to familial tumor syndromes.
This patient presented with the uncommon combination of concurrent bilateral carotid body tumors and a unilateral
glomus jugulare mass that demonstrated vascular continuity. During treatment, the patient was found to be heterozygous
for the SDHB germline mutation, an autosomal dominant genotype of the familial paraganglioma syndromes associated
with increased malignancy. The unique profile of the SDHB patient as regards primary evaluation, surgical consider-
ations, and extended surveillance was explored and has led to a proposed treatment algorithm for these patients. ( J Vasc
Surg 2012;55:216-9.)
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SA 51-year-old gentleman was referred from an ear,
nose, and throat physician following complaints of hearing
impairment that was shown on imaging to be secondary to
a skull base mass; a large ascending carotid body tumor was
concurrently noted. The patient had 2 palpable carotid
pulses and no notable cervical masses. Neurologic assess-
ment was without focal motor or sensory deficits, apart
from diminished auditory capability.
Computed tomography (CT) scanning in combination
with a previously undertaken angiogram demonstrated
masses at the right carotid bifurcation (2.7 2.3 3.7 cm)
and right jugular fossa consistent with paragangliomas
(PGLs; Fig 1). The ascending pharyngeal artery acted as a
common feeding vessel. Magnetic resonance imaging
(MRI) of the head showed an enhancing, lobulated mass
(1.7 1.5 2.4 cm) that extended through the skull base
from the internal auditory canal into the jugular foramen
(Fig 2). Further delineation of a smaller left-sided carotid
body tumor (9  8  15 mm) was undertaken during
postoperative CT angiogram imaging.
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216Surgical exploration of the right carotid mass revealed a
arge tumor (Shamblin type 3)1 that expanded into the
osterior common carotid artery and encapsulated the ca-
otid branches. An extensive dissection up to the digastricus
nded in removal of the tumor, external carotid sacrifice,
nd application of a bovine patch to the common and
nternal carotid arteries where close adherence of the tumor
ad made for difficult partition. Postoperative examination
ielded no focal motor or sensory deficits.
Due to its unilateral presentation and the increased
orbidity associated with surgical resection,2,3 the patient
lected for treatment of his glomus jugulare tumor by
adioablation. The right jugular fossa received 2400 cGy
tilizing CyberKnife radiotherapy; no regrowth was noted
t 2-year follow-up.
As regards to the left carotid body tumor, the patient
nitially refused further surgical intervention, largely due
o psychosocial issues. However, 3 years later, the patient
lected to return for resection. Removal of this mass was
omplicated by a posterior pattern of growth and incor-
oration of the vagus nerve into the dense tumor cap-
ule. Postoperative pathology of both carotid body tu-
ors yielded encapsulated tissue organized into
ellballan clusters, a finding pathognomonic to neuroen-
ocrine tumors.
Following his resections, the patient enjoyed unevent-
ul postoperative courses without neurologic or vascular
nstability. Genetic testing performed at the time of the left
arotid surgery returned positive for the sequence change
DHB, I127S (exon 4, c.380T  G, p. I127S). Consider-
ng the increased malignancy potential associated with the
DHB mutation, we recommended that the patient’s pri-
ary medical oversight be transitioned to a specialty cancer
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Volume 55, Number 1 Collins and Dietzek 217center. The patient is presently undergoing surveillance and
further testing.
DISCUSSION
Paraganglioma is a term describing neuroendocrine
tumors arising outside of the adrenal system and was first
used in 1903. These exceedingly rare neoplasms comprise
0.03% of all tumors and 0.6% of head and neck tumors.4
Within the head and neck, they arise primarily at four sites:
the carotid body at the posteromedial wall of the bifurca-
tion (50%-70%), the vagus nerve sheath ganglions (5%),
and the chief cells of the jugular bulb and along the
auricular nerve within the tympanic space (20%-40%).
Head and neck paragangliomas (HNPGLs) are part of the
diffuse neuroendocrine system but, unlike their sympa-
thetic abdominal counterpart, the pheochromocytoma,
HNPGLs are parasympathetically derived and only rarely
secrete catecholamines.5,6
The last decade has seen an increased awareness of PGL
in conjunction with discovery of gene mutations associated
with some of the known familial PGL syndromes. These
syndromes typically originate in germline mutations of the
A, B, C, and D subunits of the mitochondrial complex II
enzyme succinate dehydrogenase (SDH).7-10 Embedded
within the mitochondrial oxidation pathway, interference
with SDH is thought to lead to activation of acute and
chronic hypoxic pathways, perpetuated stimulation of
chemoreceptors, and eventual development of PGLs.11 In
Fig 1. Angiogram of right carotid body (black arrow) and glomus
jugulare masses (white arrow). Further imaging established vascu-
lar continuity between the tumors through the ascending pharyn-
geal artery.support of this pseudo-hypoxia theory, genetic markers of mypoxia such as HIF-1 and HIF-2 are typically upregu-
ated in familial PGL syndromes. Where the SDHB variant
s concerned, however, a pronounced downregulation of
hese genes is noted.12,13 This difference in expression may
e related to neoplastic potential.
SDHB gene variants are present in approximately 15%
f familial PGL patients, demonstrate autosomal dominant
iallelic expression without imprinting, and entertain a
ignificantly higher malignancy potential than the typically
ore benign SDHD and SDHC subtypes (41% vs 2%-4%).
he malignancy risk for SDHB carriers varies with neo-
lasm location, such that a propensity for HNPGLs offers a
2% lifetime risk, while extra-adrenal abdominal PGL (ab-
GL) manifestation poses a 48% chance of cancer develop-
ent. SDHB also holds the attributes of being the PGL
yndrome with the greatest prevalence of abPGL (50%-
7%) and the one least associated with exclusive HNPGL
resentation. Multicentric PGL presentation in SDHB car-
iers is about half that seen with the SDHD subtype (12%-
8% vs 30%-74%).14When combined, these factors give the
atient in this report the distinction of being one of a
andful of people recorded with his particularly rare com-
ination of concurrent PGL and a unique representative of
NPGL multicentricity in an SDHB subtype.
Although HNPGLs rarely secrete clinically significant
evels of catecholamines, SDHB carriers have an increased
ncidence of abPGL, and preoperative clinical workup is
ecommended. Historically, urine metanephrines and
lasma catecholamines were utilized in diagnosis, but
ore recent work indicates that plasma metanephrines
re the more sensitive indicator of neuroendocrine tu-
ig 2. Axial T2-weighted fluid-attenuated inversion recovery
FLAIR) magnetic resonance imaging (MRI) of glomus jugulare
umor (white arrow).or presence. Furthermore, noradrenergic phenotyping
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different hereditary PGL syndromes favor particular meta-
bolic profiles. The SDHB mutation, for example, exhibits
high levels of the dopamine metabolic byproduct methoxy-
tyramine.6
Appropriate monitoring of PGLs is an area of some
debate, although a general consensus exists for use of
whole-body scintigraphy supplemented by regular imaging
with CT and MRI.15,17,18 Due to the propensity for antic-
ipation within the familial PGL syndromes, carrier screen-
ing should start by the first or second decade of life.
Traditionally, radiologic screening was done with 111in-
Table. Recommendations for an approach to SDHB patie
Imaging
Clinical
● SDHB radionucleotide screening:
18F-FDG-PET is the preferred imaging
radiolabel with a sensitivity approaching
100%.16 Screen for PGL and establish
baseline tumor response to resection or
radioablation.
● CTA recommended for cervical tumors.
● MRA recommended for skull base tumors.
X Angiograms may be useful for assessment of
vascular continuity in unilateral masses, em-
bolization, and blood supply to skull base
tumors.
● SDHB n
the dopa
uct meth
larly elev
tions.6 E
secretion
ergic ph
X If there
or hyper
metanep
echolam
Perioperative
X Carotid and internal jugular Doppler and
clamp trials may be necessary if there is major
vessel compression by the tumor or antici-
pated operative vessel sacrifice.
X Angiograms may be warranted if skull base
PGL resection is considered due to risk of
intracranial hemorrhage.
● For patie
tive meta
echolami
due to ri
sion with
tion.
X Intraope
resection
pathetic
tonin an
Surveillance
● SDHB radionucleotide surveillance:
18F-FDG-PET is the preferred imaging
radiolabel for SDHB patients with a sensi-
tivity approaching 100%. Screening should
take place annually with supplementation
by MRI and/or CT.
● MRI and/or CT is recommended in con-
junction with whole-body scintigraphy on an
annual to biannual basis.
X Repeat m
metanep
tumor su
ing. Mal
known t
less matu
X Further
pursued
include n
ated diso
2B, NF1
abPGL, Abdominal paraganglioma; CT, computed tomography; CTA, co
positron emission tomography; HNPGL, head and neck paraganglioma; M
paraganglioma.
● Highly recommended. Bolded items are SDHB specific.
X Recommended for use only as needed.dium pentetreotide single-photon emission computed to- 6ography, but more recent advances utilizing labeled cat-
cholamines such as 18fluorodopamine (18F-FDG) show
igher specificity and sensitivity.15 For SDHB mutations
n particular, 18F-FDG-PET is the preferred imaging ra-
iolabel, with a sensitivity approaching 100%.16 Genetic
valuation is also recommended in cases of positive family
istory, abPGL, or bilateral presentation of HNPGLs; the
ncreased malignancy potential of the SDHB mutation in
articular precludes early screening of offspring. At this time,
reatment for metastatic PGL is limited and consists of com-
ined surgical excision, radioablation, chemotherapy, and ra-
iotherapeutics; 5-year survival varies between 35% and
re
oratories Outpatient
renergic screening:
breakdown prod-
yramine is particu-
in SDHB muta-
lish baseline tumor
vity and noradren-
ping.
ncerns for abPGL
n, baseline plasma
s and cat-
ay be warranted.
● SDHB surgical clearance: the in-
creased risk of malignancy and the
propensity for mixed PGL locales
necessitates a thorough preopera-
tive workup with a focus on a
staged and progressive treatment
approach.
● Suspect hypertension should be eval-
uated for primary versus secondary
causes, including noradrenergic se-
cretion.
X Establish suitability for surgery in-
volving baroreceptor organs, major
vessels of the skull base and neck,
and the potential sacrifice of those
vessels.
f concern, periopera-
rines and cat-
ould be monitored
malignant hyperten-
ical tumor manipula-
labs for HNPGL
ht include parasym-
bolites from sero-
amine.
● SDHB care transition: close com-
munication between radiation,
surgical, and oncology specialties
must take place to ensure proper
transfer of care from surgical in-
tervention to tumor surveillance.
X If chemoreceptor structures were
manipulated, monitor for barorecep-
tor failure for 6 months to 1 year
postoperatively.19,20
X Postoperative period should include
complete neurologic and vascular
exams.
xytyramine and
levels as needed for
ance and phenotyp-
t PGL have been
ress biochemically
eakdown products.
ic testing may be
s point as needed to
amilial PGL associ-
(ie, MEN2A and
L, etc.).
● Primary clinical surveillance should
be overseen by an oncology specialist
or cancer center with access to spe-
cialty radiation and radiologist ser-
vices, genetic counseling, surgical
specialists including vascular and neu-
rosurgical, and surgical oncologists of
the head, neck, abdomen, and medi-
astinal structures.
ed tomography angiography; 18F-FDG-PET, 18F-fluoro-2-deoxyglucose-
agnetic resonance angiography; MRI, magnetic resonance imaging; PGL,nt ca
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radiology, neurology, radiation-oncology, vascular surgery,
neurosurgery, and genetics may be involved in conjunction
with regular primary care oversight for the duration of the
patient’s life.
The patient in this case report came to our practice
without a clear long-term plan of care. It was only after the
second carotid body resection that the patient was geneti-
cally tested, and a plan centered on his unique and aggres-
sive germline mutation was developed. The noradrenergic
phenotyping and 18F-FDG-PET surveillance techniques
discussed here are recent developments that we include as
part of a recommended SDHB care plan (Table). Any PGL
treatment plan should be multidisciplinary in design and
developed with the goal of accommodating surgical ease of
resection, physiologic compensation, generational burden,
and the possibility of further tumor development in ana-
tomically noteworthy territory.
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